NRT 6003
Alternative Names: NRT-6003; Yttrium-90 [90Y]; Yttrium-90 carbon microspheresLatest Information Update: 30 May 2025
At a glance
- Originator Chengdu New Radiomedicine Technology
- Class Antineoplastics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Liver cancer
- Preclinical Pancreatic cancer
Most Recent Events
- 09 May 2025 Chengdu New Radiomedicine Technology initiates a Phase-III clinical trials in Liver cancer (Inoperable/Unresectable) in China (Intra-arterial) (NCT06900543)
- 03 Apr 2025 Phase-III clinical trials in Liver cancer (Inoperable/Unresectable) in China (Intra-arterial) (NCT06909708)
- 01 Apr 2025 Preclinical trials in Liver cancer in China (Intra-arterial) prior to May 2023.